

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/254334 A1

(51) International Patent Classification:

C07D 498/06 (2006.01) A61K 31/55 (2006.01)
C07D 471/16 (2006.01) A61K 31/519 (2006.01)
C07D 498/16 (2006.01) A61P 35/00 (2006.01)
A61K 31/553 (2006.01)

(21) International Application Number:

PCT/US2024/032852

(22) International Filing Date:

06 June 2024 (06.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/506,493 06 June 2023 (06.06.2023) US
63/582,474 13 September 2023 (13.09.2023) US
63/597,315 08 November 2023 (08.11.2023) US

(71) Applicant: **KUMQUAT BIOSCIENCES INC.** [US/US];
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US).

(72) Inventors: **REN, Pingda**; 10770 Wateridge Circle, Suite 120, San Diego, California 92121 (US). **WU, Baogen**; 10770 Wateridge Circle, Suite 120, San Diego, California 92121 (US). **LI, Xiaoming**; 10770 Wateridge Circle, Suite 120, San Diego, California 92121 (US). **HE, Xiaohui**; 10770 Wateridge Circle, Suite 120, San Diego, California 92121 (US). **LI, Liansheng**; 10770 Wateridge Circle, Suite 120, San Diego, California 92121 (US).

(74) Agent: **MALECHA, James**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: SUBSTITUTED HETEROCYCLES AND USES THEREOF

FIG. 1

	1	20	40
K-Ras	mte-----	---yklvvv	gagggvgsalsal tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 9)			
H-Ras	mte-----	---yklvvv	gagggvgsalsal tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 10)			
N-Ras	mte-----	---yklvvv	gagggvgsalsal tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 11)			
RalA	maankpkqqn	slalhkvimv	gsgggvgsalsal tlqfmydefv edyepatkads yrkkvvldge 60
(SEQ ID No. 12)			
RalB	maankskgqs	slalhkvimv	gsgggvgsalsal tlqfmydefv edyepatkads yrkkvvldge 60
(SEQ ID No. 13)			
	60	80	100
K-Ras	tcldildlta	gqeysamrd qymrtggegfl cvfainntks fedihhyreq	ilkrvkdssed- 108
H-Ras	tcldildlta	gqeysamrd qymrtggegfl cvfainntks fedihhyreq	ilkrvkdssed- 108
N-Ras	tcldildlta	gqeysamrd qymrtggegfl cvfainntks fedihhyreq	ilkrvkdssed- 108
RalA	evqidildta	ggedyaaaird nyfrsgegfl cvfsitemes faatadfreq	ilrvkeden 119
RalB	evqidildta	ggedyaaaird nyfrsgegfl lvfsitehes ftataefreq	ilrvkaeedk 120

(57) Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic protein.

[Continued on next page]

WO 2024/254334 A1

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*